Killing Africa with kindness
Russell Mokhiber and Robert Weissman uncover the perils and pitfalls behind a US government move to provide loans to African countries for the purchase of AIDS drugs.
the announcement of a billion-dollar-a-year US government loan programme
for African countries to buy AIDS drugs, the fight to deliver affordable
drugs to people with HIV/AIDS in Africa and elsewhere in the developing
world has entered its third phase.
drug companies' current kill-them-with-kindness scheme fails, many of
the more-than-20-million people with HIV/AIDS in Africa may finally receive
access to the treatments that could save their lives.
one of the dispute (Deny, Deny, Deny), the world's leading drug companies,
through their pricing policies, simply refused treatment to people with
HIV/AIDS in Africa. With per capita incomes in many developing countries
at less than a dollar a day, people with HIV/AIDS were simply unable to
pay the $12,000 or so a year required for the AIDS drugs cocktails that
enable many or most people with HIV/AIDS in the United States to survive.
If any developing country made noises about finding ways to provide the
drugs more cheaply, the US government - operating at the behest of the
big drug makers - threatened trade sanctions and forced them to back down.
two (Who Me?), the US government resigned from its bullying role. AIDS
activists forced the Clinton administration to reformulate its policy,
culminating in an announcement that the US government would not challenge
African countries' efforts to make generic AIDS drugs available to their
people, so long as the countries complied with World Trade Organisation
in phase three, the industry and the Clinton administration are conspiring
to kill Africans with kindness.
Through the United Nations, the industry has offered to provide discounted AIDS drugs to Africa - but at prices that remain wildly inflated over the cost of production, and far too high to be affordable to most Africans. Although no one seems to know exactly what those rates will be, many published reports suggest discounts will be in the 80% range. Such price levels almost surely will enable continued profiteering by the pharmaceutical companies from drug sales.
Africa's pain, drug Companies' gain
in July - in a move immediately denounced by a wide range of organisations
working on drug access and debt issues, including Doctors Without Borders,
Oxfam and the Health GAP coalition - the US Export-Import Bank, a government
agency, announced it would loan a billion dollars annually to African
countries for the purchase of HIV/AIDS drugs.
Ex-Im loans would pile new debt obligations on African nations at a time
when existing debt burdens are undermining the countries' ability to prevent
and treat HIV/AIDS, and when the AIDS epidemic is itself already undermining
their economic capacity to make interest payments on foreign loans.
countries' pain will be the drug manufacturers' gain. The Ex-Im loans
are to be used to buy drugs made by US companies, apparently at the highly
profitable 'discount' level provided to the UN.
like Doctors Without Borders believe that efficient procurement of generic
drugs could drop the cost of HIV/AIDS medicines an additional 90% from
the estimated drug-industry 'discounts'. That would put the cost of combination
HIV/AIDS drug therapies at approximately $200 per person per year.
insidious aspect of the Ex-Im proposal is how it will work to pre-empt
efforts by African and other developing nations to lower costs through
purchases of generic versions of AIDS drugs.
New York Times reported, 'It seems unlikely that Brazil, India or other
nations that produce such drugs for home consumption would have the export
financing available to help African nations buy the goods. The American
loans, along with a recent commitment by the World Bank to provide at
least $500 million to help African nations set up anti-AIDS initiatives,
give added incentive to African nations to treat many of their AIDS cases
with Western medicine.' ('Western' medicine means expensive, brand-name
drugs, as opposed to lower-cost generics.)
momentum for African countries to buy generic versions of the drugs, or
to acquire the technology to make their own generics, may be too great
for the industry's killer-kindness ploy to succeed.
Already, South Africa and Namibia have reportedly indicated their refusal to accept the Ex-Im loans, a welcome sign that African nations may be ready to take serious measures - irrespective of the drug industry's or the US government's desires - to provide treatment to the horrifyingly large population with HIV/AIDS.